

INVITATION



AXL inhibition as a novel treatment of aggressive disease
ASCO KOL COCKTAILS & CANAPES

Hosted by BerGenBio ASA (OSE:BGBO)

About BerGenBio

- World leaders in AXL biology – hot new target in aggressive disease, including immune evasive, therapy resistant cancer
- IPO on OSE April 2017; oversubscribed private placement (US specialist investors) April 2018
- Bemcentinib (BGB324): most advanced selective, orally bioavailable small molecule AXL inhibitor
- Six Phase II trials in combination with KEYTRUDA, targeted- and chemotherapy as well as monotherapy:
 - NSCLC
 - Melanoma
 - AML/MDS
 - TNBC
- Clinical trial collaboration with Merck & Co Inc. (NSCLC and TNBC)
- Promising early data showing benefits of AXL inhibition in idiopathic pulmonary fibrosis

**The School of the Art Institute Ballroom
112 S Michigan Ave, Chicago, IL 60603**

Saturday June 2nd 2018: 6-8 p.m. (Central)

Please [RVSP](#) Here

Speakers: Will discuss AXL biology and phase II clinical experience with bemcentinib, selective AXL inhibitor



Dr Matthew Krebs
The Christie
Manchester, UK

PI, combination trial of bemcentinib and KEYTRUDA in NSCLC
[\(Read more here\)](#)



Dr Cory Hogaboam
Cedars-Sinai Medical
LA, California

KOL, AXL's role in idiopathic pulmonary fibrosis (IPF)
[\(Read more here\)](#)



Dr David Gerber
UT Southwestern
Dallas, Texas

Sponsor investigator, combination trial of bemcentinib with docetaxel in NSCLC
[\(Read more here\)](#)



Dr Sonja Loges
Hamburg-Eppendorf
Medical Center

PI, bemcentinib monotherapy and combination in AML/MDS
[\(Read more here\)](#)



Dr Oddbjørn Straume
University of Bergen

Sponsor investigator, combination trial of bemcentinib with KEYTRUDA or BRAF inhibitors in melanoma
[\(Read more here\)](#)



Prof James Lorens
CSO BerGenBio

Scientific co-founder, Rigel Inc. and BerGenBio, AXL biology driving aggressive disease
[\(Read more here\)](#)

Please feel free to forward this invitation to interested colleagues.

Looking forward to meeting you in Chicago,
Richard Godfrey, CEO